IceCure Medical (ICCM) announced it has received regulatory approval from the Medical Device Division of Israel’s Ministry of Health for its next-generation single cryoprobe cryoablation system, the XSense System and CryoProbes. XSense is now approved in Israel for all indications for which ProSense has already received approval in Israel, including general surgery, dermatology, neurology, including cryoanalgesia, thoracic surgery, ENT, gynecology, oncology, proctology and urology.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical announces two publications for ProSense cryoablation system
- IceCure Medical files $100M mixed securities shelf
- IceCure Medical Shareholders Approve Key Agenda Items at Special Meeting
- IceCure Medical’s ProSense® Shows Promising Results in Endometriosis Treatment
- IceCure’s ProSense shows pain reduction efficacy in endometriosis study